You got your VC meeting, Now What

Oct 20, 2017

Just like your company is unique, so too are venture capitalists and their investment strategies. Many life science entrepreneurs will work hard to get the meeting, but then don’t take time to actually prepare to meet with the specific partnership.
This interactive panel discussion brings you all-star VCs for their insider perspective on how to best raise capital, what questions to ask, why it’s important to understand the life cycle of the fund, and their favorite pet peeves.

Meet the VCs:






November 1st 
5:30 – 8:30pm

JLABS —  3210 Merryfield Row
San Diego, CA 92121

Free to members  |  $40 non-members

5:30-6:30pm  —  Netwo
rking Reception;
6:30-7:30pm Panel;   7:30-8:30pm Dessert

Managing Director, Avalon Ventures

Jay Lichter is an entrepreneur and seasoned investor in the biotechnology and pharmaceutical arena with over 25 years of expertise in management, scientific research, and business development. He currently serves as president and CEO of COI Pharmaceuticals.

As managing director of Avalon Ventures, Dr. Lichter led investments in Carolus, Otonomy, Sova and Zacharon Pharmaceuticals. Dr. Lichter has served as CEO of many these companies, which has included leading both their business and scientific operations during the companies’ formative periods. He is on the board of directors for most of these companies and also served as Chairman of the Board of RQx, another Avalon company. He led the first life science investments for the Avalon IX portfolio, Sova Pharmaceuticals, and serves as its CEO and board member. He also led the investment in Aratana Therapeutics, where he serves as chairman of the board. Dr. Lichter took over the leadership of Avelas in order to turn that company around after a change in management and serves as a director on the board. Dr. Lichter is the inventor on over 260 patent and patent applications for six Avalon portfolio companies, including 78 issued patents. Dr. Lichter has been involved in licensing or merger and acquisition deals valued in excess of $1 billion.

In addition to his Avalon activities, Dr. Lichter serves as a director on the board of the John Wayne Cancer Institute and a trustee and Chairman to Pacific Ridge School located in Carlsbad.

Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. Dr. Lichter obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign

Partner, Domain

Kim joined Domain in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Kim has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine.

Present board memberships include Epic Sciences, Neothetics, Obalon Therapeutics, Omniome, ROX Medical, Sera Prognostics, and Tragara Pharmaceuticals.  She was formerly a board member of Syndax Pharmaceuticals.  Kim was also involved with Ariosa Diagnostics until the company was sold to Roche in January 2015, Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to sanofi-aventis in April 2009.

Prior to Domain, Kim was a Kauffman Fellow with MPM Capital. Prior to joining MPM, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Kim is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.

Kim serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and of Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego’s CONNECT Foundation.

Venture Partner, SV Health Investors

Prior to joining SV, Dan was founder, President and CEO of Rempex Pharmaceuticals, Inc. (SVLS Fund V), an antibiotic company that was sold to the Medicines Company two years after its founding in a transaction valued at up to $475 million. Previously Dan was President and CEO of Mpex Pharmaceuticals, Inc. (SVLS Fund IV), a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials; the drug was acquired by Aptalis, Inc. in 2011. Dan has also held senior executive positions at a number of other biotechnology companies. He served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion.

Dan holds the following external Board seats: Nabriva Therapeutics (Chairman, NASDAQ:NBRV), Atox Bio (Chairman), Cidara Therapeutics (NASDAQ: CDTX) and Arbutus Biopharma (NASDAQ: ABUS). He is also Chairman of Biocom, the life science industry association of California that represents more than 800 member companies. In his spare time, Dan is an avid golfer and also dabbles in the music industry.

CEO, Canale Communications

Carin Canale is CEO of Canale Communications Inc., where she also serves as the chief culture officer, principal strategist and resident sommelier. In her role as CEO, Carin works closely with client teams, having provided senior level strategy to more than 300 life science companies of all shapes and sizes ranging from pre-series A financing to billion dollar public companies such as Amgen and Johnson & Johnson. Through her career in life science communications, she has advised a diverse range of companies including biotechnology, biopharmaceutical, medical device, diagnostics, research organizations and providers of enabling technologies.

In addition to client services, Carin is actively involved in the life science community and is the vice chair of the board of directors for BIOCOM, Southern California’s life science trade association, and immediate past chair of the San Diego Venture Group.  Under Carin’s leadership, CanaleComm received the Best Places to Work award from the San Diego Business Journal in 2016 and 2017. Carin has also received numerous life science leadership awards for leadership in business. An active member of the Mission Hills Town Council, Carin was also named “Woman of the Year” in 2016 by California Assembly Speaker Emeritus Toni Atkins.

Prior to founding Canale Communications, Carin was president of the life sciences division of international public relations firm Porter Novelli, managing teams in San Diego, Los Angeles, Boston and New York. Carin joined Porter Novelli when the firm acquired boutique life sciences communication firm, Atkins + Associates, in which Carin was partner and managing director.